Cipla Limited
CIPLA
Rang in Aktien
#1818
Cipla Limited, along with its associated entities, operates as a global... Cipla Limited, along with its associated entities, operates as a global pharmaceutical enterprise, specializing in the creation and distribution of a wide array of medicinal products. Its extensive portfolio includes both active pharmaceutical ingredients (APIs) and a diverse range of finished formulations, addressing numerous therapeutic areas such as cardiovascular diseases, metabolic disorders, HIV, respiratory conditions, urology, oncology, pediatric health, infectious diseases, critical care, hepatitis, women's health, ophthalmology, and neuropsychiatry. The company maintains a strong focus on respiratory treatments, offering various inhalers, nasal sprays, injectables, and biosimilars. Cipla has also forged significant partnerships, including a licensing arrangement with Merck & Co., Inc. for the manufacturing and commercialization of the investigational oral antiviral drug Molnupiravir, and a separate license agreement with Eli Lilly and Company for baricitinib, indicated for COVID-19. Furthermore, it collaborates with Dr. Reddy's Laboratories Ltd, Sun Pharmaceutical Industries Limited, Emcure Pharmaceuticals Limited, and Torrent Pharmaceuticals Limited for Molnupiravir's clinical trials. Established in 1935, Cipla's corporate headquarters are located in Mumbai, India.
Aktienkurs
$14.61
Marktkapitalisierung
$11.80B
Veränderung (1 Tag)
-0.12%
Veränderung (1 Jahr)
-18.47%
Land
IN
Handel Cipla Limited (CIPLA)
Kategorie
Healthcare
P/S-Verhältnis für Cipla Limited (CIPLA)
P/S-Verhältnis zum October 2026 TTM: 3.82
Laut den neuesten Finanzberichten und dem Aktienkurs von Cipla Limited beträgt das aktuelle Kurs-Umsatz-Verhältnis (TTM) 3.82. Am Ende des Jahres 2024 lag das P/S-Verhältnis bei 4.74.
P/S-Verlauf für Cipla Limited von 2004 bis 2026
P/S-Verhältnis zum Jahresende
| Jahr | P/S-Verhältnis | ändert |
|---|---|---|
| 2026 (TTM) | 3.82 | -10.80% |
| 2025 | 4.28 | -9.65% |
| 2024 | 4.74 | 47.08% |
| 2023 | 3.22 | -14.85% |
| 2022 | 3.78 | 10.05% |
| 2021 | 3.44 | 72.27% |
| 2020 | 2.00 | -23.06% |
| 2019 | 2.59 | -15.52% |
| 2018 | 3.07 | -7.69% |
| 2017 | 3.33 | 9.59% |
| 2016 | 3.03 | -39.81% |
| 2015 | 5.04 | 86.12% |
| 2014 | 2.71 | -27.40% |
| 2013 | 3.73 | 6.94% |
| 2012 | 3.49 | -98.05% |
| 2011 | 179.33 | 3,495.17% |
| 2010 | 4.99 | 44.67% |
| 2009 | 3.45 | -19.14% |
| 2008 | 4.26 | -20.21% |
| 2007 | 5.34 | -22.03% |
| 2006 | 6.85 | 94.90% |
| 2005 | 3.52 | -7.98% |
| 2004 | 3.82 | 0.00% |
P/S-Verhältnis für ähnliche Unternehmen oder Wettbewerber
| Unternehmen | P/S-Verhältnis | P/S-Verhältnis-Differenz | Land |
|---|---|---|---|
| - | - |
DE
|
|
| - | - |
DE
|
|
| - | - |
JP
|
|
| - | - |
CH
|
|
| 7.06 | 84.88% |
IN
|
